Key Insights on Gross Profit: Bristol-Myers Squibb Company vs Pharming Group N.V.

Bristol-Myers vs. Pharming: A Decade of Financial Growth

__timestampBristol-Myers Squibb CompanyPharming Group N.V.
Wednesday, January 1, 20141194700000021595165
Thursday, January 1, 2015126510000006590427
Friday, January 1, 20161448100000011768542
Sunday, January 1, 20171471000000092587038
Monday, January 1, 201816014000000129203843
Tuesday, January 1, 201918067000000165412447
Wednesday, January 1, 202030745000000203056430
Friday, January 1, 202136445000000169670071
Saturday, January 1, 202236022000000188060000
Sunday, January 1, 202334313000000220104000
Monday, January 1, 202436351000000
Loading chart...

Unleashing the power of data

A Tale of Two Companies: Bristol-Myers Squibb vs. Pharming Group

In the ever-evolving pharmaceutical industry, the financial health of companies is a key indicator of their market position and potential for innovation. Over the past decade, Bristol-Myers Squibb Company has demonstrated a robust growth trajectory in gross profit, with a remarkable increase of nearly 187% from 2014 to 2023. This growth underscores its strategic investments and successful product launches. In contrast, Pharming Group N.V., while significantly smaller, has shown a steady upward trend, with its gross profit increasing by over 900% during the same period. This growth, albeit from a smaller base, highlights Pharming's potential in niche markets. The data from 2020 to 2023 is particularly telling, as Bristol-Myers Squibb's gross profit peaked in 2021, while Pharming Group continued its upward climb, reflecting resilience and adaptability in a competitive landscape.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025